Physician profile
Nathan Oldham
NPI 1780883843
$1,152.57
in general payments reported to CMS, 2019-2025
18 companies · $29.30 in 2025
The $29.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $14.08 · 2021: $11.11 · 2022: $64.37 · 2023: $193 · 2024: $172 · 2025: $29.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.08 | 2021-2025 | |
| Glaxosmithkline, LLC. | $139.60 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $123.80 | 2019 | |
| Lilly USA, LLC | $97.82 | 2019-2023 | Mounjaro |
| Pfizer INC. | $75.80 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $74.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $49.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.21 | 2019 | |
| Celgene Corporation | $31.08 | 2019 | |
| Amgen INC. | $21.53 | 2019 | |
| Merck Sharp & Dohme LLC | $16.71 | 2022 | |
| Genzyme Corporation | $15.14 | 2019 | |
| Amarin Pharma, INC. | $13.44 | 2019 | |
| Sumitomo Pharma America, INC. | $12.30 | 2023 | Gemtesa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11.88 | 2019 | |
| Novo Nordisk INC | $11.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Oldham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.